April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Intravenous Pulsed Corticosteroids for Ocular Inflammatory Diseases
Author Affiliations & Notes
  • L. D. Charkoudian
    Emory Eye Center, Emory University, Atlanta, Georgia
  • G.-S. Ying
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania
  • J. E. Thorne
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • C. Foster
    Ophthalmology, Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts
  • D. A. Jabs
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • G. A. Levy-Clarke
    St Lukes Cataract and Laser Institute, St Petersburg, Florida
  • R. B. Nussenblatt
    National Eye Inst/NIH, Bethesda, Maryland
  • J. T. Rosenbaum
    Ophthalmology, Casey Eye Institute-OHSU, Portland, Oregon
  • E. B. Suhler
    Uveitis Clinic, Casey Eye Institute-OHSU/Portland VAMC, Portland, Oregon
  • J. H. Kempen
    Ophthalmology/Biostatistics&Epidemiology, Scheie Eye Inst/Univ of Penn, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  L.D. Charkoudian, None; G.-S. Ying, None; J.E. Thorne, None; C. Foster, Eyegate, I; Allergan, C; Bausch & Lomb, C; Sirion, C; Allergan, R; Bausch & Lomb, R; Alcon, R; Inspire, R; Ista, R; Centocor, R; D.A. Jabs, Alcon, C; Roche Pharmaceuticals, C; Genzyme Corp., C; Novartis, C; Allergan, C; Glaxo Smith Kline, C; Applied Genetic Technologies Corporation, C; The Emmes Corporation, C; The Johns Hopkins Dana Center for Preventive Ophthalmology, C; G.A. Levy-Clarke, None; R.B. Nussenblatt, None; J.T. Rosenbaum, Amgen, I; Abbott, C; ESBATech, C; Lux Biosciences, C; Centocor, C; Genentech, C; E.B. Suhler, None; J.H. Kempen, Alcon, C; Lux Biosciences, C.
  • Footnotes
    Support  This study was supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. D. Charkoudian, G.-S. Ying, J. E. Thorne, C. Foster, D. A. Jabs, G. A. Levy-Clarke, R. B. Nussenblatt, J. T. Rosenbaum, E. B. Suhler, J. H. Kempen; Intravenous Pulsed Corticosteroids for Ocular Inflammatory Diseases. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5257.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for non-infectious ocular inflammatory diseases.

Methods: : 108 eyes of seventy patients receiving pulsed intravenous corticosteroids for control of non-infectious ocular inflammatory disease were retrospectively identified at five centers. Visual acuity, level of inflammation, ocular examination features, and ocular or systemic complications were recorded by medical record review at every visit.

Results: : Approximately one-half of eyes achieved complete control of inflammation at one month after initiation of treatment (57%; 95% CI: 33-83%) and the majority of eyes achieved at least partial control (82%; 95% CI: 61-96%). By disease subtype, 54.7% (95% CI: 29.8-83.0%) of eyes with intraocular inflammatory disease attained complete control at one month versus 51.9% (95% CI: 25.6-83.7%) of non-uveitic eyes (mucous membrane pemphigoid, scleritis, etc.). Overall, most eyes (85%; 95% CI: 70-95%) exhibited clinically significant improvement in anterior chamber inflammation, whereas vitreous cells were less responsive (48%; 95% CI: 32-67%). There was a trend towards achieving 20/40 or better vision at one month (p=0.06). One patient developed a colon perforation during the three days of treatment and one had difficulty controlling diabetes mellitus following the infusion. No other systemic complications were recorded.

Conclusions: : Treatment of ocular inflammation with pulsed intravenous corticosteroids appears to be effective at one month for all major forms of ocular inflammatory disease. Minimal ocular and systemic complications were observed as a side effect of treatment. Further studies and follow-up are needed to fully investigate the potential of this therapy.

Keywords: inflammation • uvea • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.